SCHEMBL995638

SCHEMBL995638

O=S(=O)(Cl)c1ccc(C23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
LMNA P02545 4/20 0.53
NPC1 O15118 2/20 0.46
EPHX2 P34913 4/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 2/20 0.44
GAA P10253 1/20 0.44
GFER P55789 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
RAB9A P51151 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
SERPINE1 P05121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14836225 0.83 LMNA (0.55) ALDH1A1LMNANPC1EPHX2MEN1
SCHEMBL2742120 0.81 ALDH1A1 (0.53) ALDH1A1LMNANPC1EPHX2MEN1
SCHEMBL2763437 0.79 LMNA (0.77) ALDH1A1LMNANPC1EPHX2MEN1
SCHEMBL14836389 0.79 GRIN2D (0.51) ALDH1A1LMNANPC1EPHX2MEN1
SCHEMBL18705090 0.74 LMNA (0.63) ALDH1A1LMNANPC1EPHX2MEN1
SCHEMBL5346553 0.74 LMNA (0.63) ALDH1A1LMNANPC1EPHX2MEN1
Potassium Ion SCHEMBL31649385 0.74 MEN1 (0.50) ALDH1A1LMNANPC1EPHX2MEN1
SCHEMBL13609501 0.73 LMNA (0.57) ALDH1A1LMNANPC1EPHX2MEN1
Lithium Ion SCHEMBL31615854 0.72 LMNA (0.61) ALDH1A1LMNANPC1EPHX2MEN1
SCHEMBL15468976 0.72 LMNA (0.61) ALDH1A1LMNANPC1EPHX2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692062-A1 NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME Amorepacific Corporation (KR) 2026-02-11 EP claimed
WO-2024205303-A1 NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME (주)아모레퍼시픽 2024-10-03 WO claimed
US-20260144730-A1 COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND AMOREPACIFIC CORPORATION (KR) 2026-05-28 US disclosed
US-20260083715-A1 COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND AMOREPACIFIC CORPORATION (KR) 2026-03-26 US disclosed
EP-4692062-A1 NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME Amorepacific Corporation (KR) 2026-02-11 EP disclosed
WO-2024205303-A1 NOVEL AMIDE-BASED COMPOUND AND COMPOSITION COMPRISING SAME (주)아모레퍼시픽 2024-10-03 WO disclosed
EP-2456435-B1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE UNIV LELAND STANFORD JUNIOR (US) 2015-06-24 EP disclosed
US-20140012032-A1 METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS PIRAMAL IMAGING SA (CH) 2014-01-09 US disclosed
EP-2575900-A1 METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS Piramal Imaging SA (CH) 2013-04-10 EP disclosed
US-20120225862-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE AUCKLAND UNIVSERVICES LIMITED (NZ) 2012-09-06 US disclosed
EP-2456435-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE The Board of Trustees of The Leland Stanford Junior University (US) 2012-05-30 EP disclosed
WO-2011151281-A1 METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-08 WO disclosed
WO-2011011514-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144730-A1 COMPOSITION FOR SKIN ANTI-AGING, SKIN BRIGHTENING OR SKIN REVERSE-AGING CONTAINING AMIDE-BASED COMPOUND TYR, ATG13, ARGLU1 ALDH1A1 1443/4885LMNA 147/4885NPC1 2378/4885
US-20260083715-A1 COMPOSITION FOR ENHANCING IMMUNITY CONTAINING AMIDE-BASED COMPOUND ARG1, MSR1, TLR1 ALDH1A1 3501/4885LMNA 3265/4885NPC1 285/4885
US-20120225862-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE BRDT, NISCH, PAICS ALDH1A1 1336/4885LMNA 575/4885NPC1 2057/4885
US-20140012032-A1 METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS APP, APBA1, BACE1 ALDH1A1 2534/4885LMNA 1240/4885NPC1 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.